Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

Chronic HBV Infection Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics of Single Ascending Dose (SAD) of PA1010 Tablets in Chinese Healthy Subjects and the Effects of Food and Gender on Pharmacokinetics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05468060
• Other study ID #: PA1010-101
• Status: Completed
• Phase: Phase 1
• Start date: June 28, 2020
• Est. completion date: December 12, 2020

Study information

• Verified date: July 2022
• Source: Zhejiang Palo Alto Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetics characteristics of single ascending dose (SAD) of PA1010 tablets in Chinese healthy adults and the impact of food and gender on the pharmacokinetics

Description:

Stage I: Single dose, Single Ascending Dose (SAD) This is a randomized, double-blind, placebo-controlled, dose-escalation clinical trial. The objective is to evaluate the safety, tolerability and pharmacokinetics characteristics of PA1010 tablets in Chinese healthy subjects. There are six dose groups of PA1010 ( 5 mg、10 mg、20 mg、30 mg、45 mg and 60 mg) proposed to be tested sequentially in this study. A total of 60 healthy subjects are planned to be enrolled in this study and will be randomly assigned to the corresponding dose group in equal proportion, stratified by gender (male vs female). 10 subjects in each dose group are randomly assigned in a ratio of 4:1 to receive PA1010 tablets or placebo. All subjects will be dosed in a single dose, and the dose-related safety, tolerability and PK of PA1010 will be evaluated. Stage II: Study on the effect of food on Pharmacokinetics This is a single center, randomized, open, two group crossover, self-control clinical trial. A total of 20 subjects are planned to be enrolled in this study, and will be randomly assigned to a dosing order (i.e. fasting administration followed by high-fat meal administration, or high-fat meal administration followed by fasting administration) in a ratio of 1:1. Subjects will be dosed 10 mg PA1010 tablets in a single dose, and the food-related PK of PA1010 will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 12, 2020
• Est. primary completion date: December 12, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects aged between 18 and 55 (including upper and lower limits);

2. Body mass index (BMI) is between 18 and 28 kg/m2 (including upper and lower limits);

3. During the study period (from signing the informed consent to the last follow-up) and within 90 days after the last dose, there is no possibility of pregnancy (or making

the sexual partner pregnant), childbirth or lactation, including:

1. Menopausal women who have menopause for more than 12 months or undergo sterilization (such as hysterectomy or bilateral ovariectomy);

2. Postmenopausal women, who have negative urine pregnancy test within 24 hours before the first dose, are willing to take more than one effective contraceptive method from the screening period to 90 days after the last dose, including intrauterine device, fallopian tube ligation, double barrier method (condom / vaginal diaphragm + spermicide) and male partner vas deferens ligation, but do not include oral contraceptives;

3. Men are willing to take more than one effective contraceptive method from the first dose to 90 days after the last dose, including vasectomy, double barrier method, female partner's use of contraceptives, intrauterine device or tubal ligation, etc.;

4. Avoid sex during the study period to 90 days after the last dose;

4. There is no history of major diseases, and the physical examination, vital signs, electrocardiogram and laboratory examination results during the screening period are normal, or although they exceed the normal reference value range, they are judged by the researcher to be of no clinical significance;

5. Be able to communicate with clinical staff normally and comply with the requirements of this study;

6. Sign the informed consent form to indicate willingness to participate in this study.

Exclusion Criteria:

1. Any medical condition that the investigator considers to be likely to increase the risk of study participation (in particular, a history of esophageal or gastrointestinal ulcers), that may interfere with drug absorption, distribution, metabolism, or excretion, or that may impair adherence to the study protocol;

2. Those who have received any other study drug within 90 days before the first dose of the study drug;

3. Those who have received other prescription or over-the-counter drugs that will effect the study evaluation considered by the investigator that within 14 days prior to the first administration of the study drug (or within 5 half-lives of the drug, whichever is longer);

4. Those who have donated blood or lost a lot of blood (>400 ml) within 3 months before the first dose of the study drug;

5. Major surgery or great trauma within 6 months before the first dose of the study drug (the investigator make the judgement based on the previous medical history);

6. Consumption of beverages or foods containing grapefruit, pomegranate, papaya, grapes, carambola within 14 days, or do not agree to refrain from taking those beverages or foods every day during the study;

7. Any alcoholic products within 48 hours before the first administration of the study drug, or disagree to refrain from taking any alcohol products every day during the study;

8. Any foods or beverages rich in caffeine and xanthine within 48 hours before the first dose of the study drug(coffee, tea, coke, chocolate, seafood, animal liver, etc.) or disagree to refrain from taking those foods and beverages every day during the study;

9. Abnormal ECG during screening or baseline period, which is judged to be clinically significant by the investigator; Or QTcF > 450 ms during screening or baseline period;

10. History of heart disease, including a family history of sudden death caused by cardiac causes or QT interval prolongation syndrome;

11. History of serious kidney disease (judged by the investigator);

12. Difficulty in venous blood collection, or known to have a history of needle fainting and blood fainting for many times;

13. Clinical or laboratory evidence shows that there is one of the following situations:

hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis carrying / infection;

14. Any history of food and drug allergy of clinical significance judged by the investigator;

15. Any history of drug abuse or urine drug test (+) in the screening period within 1 year before the first administration of the study drug;

16. Regular drinking history within 6 months before screening. Women have more than 7 cups / week, men have more than 14 cups / week (1 cup =5 ounces of wine or 12 ounces of beer or 1.5 ounces of spirits) or the alcohol test exceeds the standard during the screening period;

17. Those who cannot quit smoking as required during the study period or whose cigarette test paper (urine nicotine test) is positive during the screening period;

18. Participated in this study before.

Related Conditions & MeSH terms

• Chronic HBV Infection

Intervention

Drug:
• PA1010
Placebo as control

Locations

Country	Name	City	State
China	Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Palo Alto Pharmaceuticals, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects having abnormal hematology laboratory parameters	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal clinical chemistry parameters	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal values for urinalysis	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal with blood coagulation function	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Ear temperature	Vital sign-ear temperature	Up to 72 hours after last dose
Primary	Systolic and diastolic blood pressure	Vital sign-Systolic and diastolic blood pressure	Up to 72 hours after last dose
Primary	Pulse rate	Vital sign-Pulse rate	Up to 72 hours after last dose
Primary	Breathing rate	Vital sign-Breathing rate	Up to 72 hours after last dose
Primary	ECG parameter-QTc interval	A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals	Up to 72 hours after last dose
Primary	ECG parameter-PR interval	A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals	Up to 72 hours after last dose
Primary	ECG parameter-QRS duration	A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration	Up to 72 hours after last dose
Primary	Number of subjects experiencing adverse events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.	Up to 4days after the last dose
Primary	Pharmacokinetics of single dose of PA1010-Cmax	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)	Up to 72 hours after last dose
Primary	Pharmacokinetics of single dose of PA1010-Tmax	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)	Up to 72 hours after last dose
Primary	Pharmacokinetics of single dose of PA1010-AUC	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)	Up to 72 hours after last dose
Secondary	Pharmacokinetics of single dose of PA1010-T1/2	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2)	Up to 72 hours after last dose
Secondary	Pharmacokinetics of single dose of PA1010-Vz/F	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Volume of Distribution(Vz/F)	Up to 72 hours after last dose
Secondary	Pharmacokinetics of single dose of PA1010-?z	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Rate Constant(?z)	Up to 72 hours after last dose
Secondary	Pharmacokinetics of single dose of PA1010-CL/F	Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Clearance(CL/F)	Up to 72 hours after last dose